GO
Loading...

Biogen Idec Inc

More

  • Oct 22- Biogen Idec Inc on Wednesday reported much higher-than-expected third-quarter profit and the company raised its full-year earnings forecast, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. Citing updated business development expectations, Biogen raised its...

  • Oct 22- Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. The U.S. biotechnology company's net profit jumped to $856.1 million, or $3.62 per share, from $487.6 million, or $2.05 per share, a year ago.

  • Biogen slides as MS drug is linked to inflammation Wednesday, 22 Oct 2014 | 7:24 AM ET

    CAMBRIDGE, Mass.— Shares of Biogen Idec slumped 8 percent Wednesday despite a strong quarter after the pharmaceutical said a patient who took its newest multiple sclerosis drug suffered a brain inflammation and later died. The company confirmed there was a case of progressive multifocal leukoencephalopathy, or PML, in one patient who took the drug Tecfidera.

  • Asia stocks down on mixed China data, weak Wall St Wednesday, 22 Oct 2014 | 1:28 AM ET

    NEW YORK— Stocks fell broadly on Wednesday, snapping a four-day winning streak for the Standard& Poor's 500 index, as investors shaken by recent swings in the market sold some of their holdings. "The market is still nervous," said John Manley, chief equity strategist at Wells Fargo Funds Management. Stocks were higher most of the morning on hopes that the European...

  • Earnings set to take markets' center stage Tuesday, 21 Oct 2014 | 7:29 PM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • Final Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 6:01 PM ET

    Amgen Inc. rose $6.58 or 4.8 percent, to $144.09. Biogen Idec rose $15.36 or 4.9 percent, to $326.77. Celgene Corp. rose $2.97 or 3.2 percent, to $94.97.

  • Midday Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 1:43 PM ET

    Amgen Inc. rose $1.96 or 1.4 percent, to $139.47. Biogen Idec rose $8.12 or 2.6 percent, to $319.53. Celgene Corp. rose $2.57 or 2.8 percent, to $94.57.

  • Early Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 11:56 AM ET

    Amgen Inc. rose $1.55 or 1.1 percent, to $139.06. Biogen Idec rose $6.48 or 2.1 percent, to $317.89. Celgene Corp. rose $3.34 or 3.6 percent, to $95.34.

  • Final Glance: Biotechnology companies Monday, 20 Oct 2014 | 6:05 PM ET

    Amgen Inc. rose $3.82 or 2.9 percent, to $137.51. Biogen Idec rose $4.70 or 1.5 percent, to $311.41. Celgene Corp. rose $3.88 or 4.4 percent, to $92.00.

  • Midday Glance: Biotechnology companies Monday, 20 Oct 2014 | 1:23 PM ET

    Amgen Inc. rose$. 35 or. 3 percent, to $134.04. Biogen Idec rose $3.41 or 1.1 percent, to $310.12. Celgene Corp. rose $3.24 or 3.7 percent, to $91.36.

  • Early Glance: Biotechnology companies Monday, 20 Oct 2014 | 10:40 AM ET

    Amgen Inc. rose$. 93 or. 7 percent, to $134.62. Biogen Idec rose $2.07 or. 7 percent, to $308.78. Celgene Corp. rose $1.72 or 2.0 percent, to $89.84.

  • Final Glance: Biotechnology companies Friday, 17 Oct 2014 | 6:03 PM ET

    Amgen Inc. rose $3.24 or 2.5 percent, to $133.69. Biogen Idec rose $3.97 or 1.3 percent, to $306.71. Celgene Corp. rose $1.74 or 2.0 percent, to $88.12.

  • Midday Glance: Biotechnology companies Friday, 17 Oct 2014 | 1:21 PM ET

    Amgen Inc. rose $3.30 or 2.5 percent, to $133.75. Biogen Idec rose $9.17 or 3.0 percent, to $311.91. Celgene Corp. rose $3.04 or 3.5 percent, to $89.42.

  • Early Glance: Biotechnology companies Friday, 17 Oct 2014 | 10:39 AM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $130.70. Biogen Idec rose $8.00 or 2.6 percent, to $310.74. Celgene Corp. rose $2.45 or 2.8 percent, to $88.83.

  • Final Glance: Biotechnology companies Thursday, 16 Oct 2014 | 6:02 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $130.45. Biogen Idec fell $2.95 or 1.0 percent, to $302.74. Celgene Corp. fell$. 17 or. 2 percent, to $86.38.

  • Midday Glance: Biotechnology companies Thursday, 16 Oct 2014 | 1:21 PM ET

    Amgen Inc. fell $1.85 or 1.4 percent, to $129.05. Biogen Idec fell $2.23 or. 7 percent, to $303.46. Celgene Corp. fell$. 18 or. 2 percent, to $86.37.

  • Early Glance: Biotechnology companies Thursday, 16 Oct 2014 | 11:35 AM ET

    Amgen Inc. fell $1.81 or 1.4 percent, to $129.09. Biogen Idec fell $2.69 or. 9 percent, to $303.00. Celgene Corp. fell $1.56 or 1.8 percent, to $84.99.

  • Oct 16- Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow. The company, whose profit topped expectations for the fourth straight quarter, cut its 2014 earnings forecast to $4.86- $4.89 per share to exclude gains from its vaccine business that it...

  • Final Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 6:07 PM ET

    Amgen Inc. fell $1.30 or 1.0 percent, to $130.90. Biogen Idec rose $4.11 or 1.4 percent, to $305.69. Celgene Corp. rose$. 07 or. 1 percent, to $86.55.

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...